Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer

in

Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer

CNNMoney.com (press release) - 30 minutes ago
CORONA , Calif . , Nov . 13 / PRNewswire - FirstCall / - - Watson Pharmaceuticals , Inc . ( NYSE : WPI ) , a leading specialty pharmaceutical company , today announced that its New Drug Application ...